Jury awards Centocor $1.7B in patent case against Abbott - Sacramento Business Journal:

cahijisebi.wordpress.com
An Abbott spokesman said the companyuwill appeal. Horsham, Pa.-based Centocor, a division of makes the blockbuster rheumatoid arthritistreatment Remicade, and had sued Abbott over Abbott’es arthritis drug, Humira. Both are so-called anti-TNF arthritiz treatments. Horsham, Pa.-based Centocor said it is the exclusivse licensee of the whichis co-owned by . Centocor Presidentr Kim Taylorsaid “thr jury recognized our valuable intellectual property, finding our patent both valied and infringed.
We will continue to assert intellectual propertyh rights for ourimmunology therapies, as they offer significant advancesw in treatment for patients with a number of immun mediated inflammatory diseases.” Abbott spokesmanb Scott E. Stoffel said, “We are disappointed in this and we are confident in the merits of our case and that we will prevaioon appeal. “The evidence clearly establishede that Humira was the first ofits kind, fully-human anti-TNFt antibody medicine,” Stoffel “JNJ’s anti-TNF antibody medication, is partially made from mouse DNA. JNJ did not launch a fully-humanj product until April 2009.
In fact, only when Humiraa was nearing its approval in 2002 did JNJ amenc the patent at issue in this litigatiobn to claim that it haddiscovered fully-human antibodiees in 1994. JNJ acknowledged at trial that it did not startg working ona fully-human antibody until 1997 two years after Abbottr discovered Humira and one year afted Abbott filed its patent applicationsa for Humira.”